Eeva System (Auxogyn) shows positive results in trial for IVF

A new study shows that the Early Embryo Viability Assessment (Eeva) Test from Auxogyn is able to predict embryo advancement in IVF (In vitro fertilisation) treatment with a new level of accuracy. In a prospective multi-center cohort study of 160 patients and close to 1,800 embryos, the Eeva Test was able to predict blastocyst formation at the cleavage stage with 85 percent specificity, reducing the false positive rate from 43 percent to 15 percent compared with traditional morphology selection. Eeva also demonstrated the ability to track and analyze cell division timings with greater than 90 percent accuracy. Additionally, Eeva was able to increase the consistency of embryo assessment across embryologists. With these results, the company expects to receive CE clearance for Eeva in the EU imminently and is also on track to submit 510(k) filing to the FDA in July 2012. Clinical data were presented at the European Society of Human Reproduction and Embryology (ESHRE) Annual Meeting.